Investors One Pager Q1-2012 • BioMarCare Technologies is a Hadasit Bio-Holdings (TASE: HDST) Portfolio Company. • The company initiated operations in Q3/2009 and is based in Israel. • Our technologies are based on revolutionary research and pioneering publications by world renowned scientists who are recognized as key opinion leaders in tumor biology and cancer genetics. • The company is currently seeking a strategic alliance and/or investment funding of $3M for clinical studies and product development. BioMarCare intends to build a rich pipeline of multi-biomarker cancer testing kits based on combinations of novel biomarkers being discovered on an ongoing basis in academic research centers such as Hadassah Medical Center , the company's "home base". The company intends to leverage its access to Hadassah's vast clinical research resources in order to conduct rigorous validation studies, and to utilize its executive team members' expertise in assay development to generate high performance diagnostic assays with proven clinical efficacy.

#_lt#p style="text-align#_sc# left; color#_sc# #595454; font-weight#_sc# bold;"#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="font-size#_sc# medium;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454;"#_gt#Investors#_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/p#_gt# #_lt#p style="text-align#_sc# left; color#_sc# #595454; font-weight#_sc# bold;"#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="font-size#_sc# medium;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="font-size#_sc# medium;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span#_gt##_lt#a style="font-size#_sc# 14px;" href="http#_sc#//www.investors.biomarcare.com/BRPortalStorage/a/52/91/51-RxX69EepH9.pdf" target="_parent"#_gt#One Pager Q1-2012#_lt#/a#_gt##_lt#/span#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="font-size#_sc# medium;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454;"#_gt# #_lt#/span#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="font-size#_sc# medium;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span#_gt##_lt#img style="height#_sc# 26px;" src="http#_sc#//www.investors.biomarcare.com/BRPortalStorage/b/29/81/94-SiQfrxC9Aw.jpg" alt="" height="28"#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#br#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/p#_gt# #_lt#div style="text-align#_sc# left; direction#_sc# ltr; color#_sc# #595454; font-size#_sc# 14px;"#_gt# #_lt#table style="width#_sc# 717px; height#_sc# 154px;" border="0"#_gt# #_lt#tbody#_gt# #_lt#tr#_gt# #_lt#td style="width#_sc# 657px;" align="left" valign="top"#_gt##_lt#span style="font-size#_sc# medium;"#_gt# #_lt#div style="text-align#_sc# justify; direction#_sc# ltr; color#_sc# #000000; font-size#_sc# 14px;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#strong#_gt#•#_lt#/strong#_gt#  BioMarCare Technologies is a #_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#a style="font-size#_sc# 14px;" href="http#_sc#//www.ab.biomarcare.com/BRPortal/br/P102.jsp?arc=67057" target="_blank"#_gt#Hadasit Bio-Holdings#_lt#/a#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt# (TASE#_sc# HDST) Portfolio Company.#_lt#br#_gt##_lt#strong#_gt#•#_lt#/strong#_gt#  The company initiated operations in Q3/2009 and is based in Israel.#_lt#br#_gt##_lt#strong#_gt#•#_lt#/strong#_gt#  Our technologies are based on revolutionary research and pioneering publications by world renowned scientists who are recognized as key opinion leaders in tumor biology and cancer genetics.#_lt#br#_gt##_lt#strong#_gt#•#_lt#/strong#_gt#  The company is currently seeking a strategic alliance and/or investment funding of $3M for clinical studies and product development.#_lt#/span#_gt##_lt#/div#_gt# #_lt#div style="text-align#_sc# justify; direction#_sc# ltr; color#_sc# #000000; font-size#_sc# 14px;"#_gt# #_lt#/div#_gt# #_lt#div style="text-align#_sc# justify; direction#_sc# ltr; color#_sc# #000000; font-size#_sc# 14px;"#_gt##_lt#span style="color#_sc# #595454;"#_gt#BioMarCare intends to build a rich pipeline of multi-biomarker cancer testing kits based on combinations of #_lt#span style="font-size#_sc# small;"#_gt##_lt#span style="font-family#_sc# Arial; color#_sc# #595454; font-size#_sc# 10pt;"#_gt##_lt#a target="_blank" href="http#_sc#//www.tec.biomarcare.com/BRPortal/br/P102.jsp?arc=91868" target="_blank"#_gt##_lt#span style="color#_sc# #595454; font-size#_sc# small;"#_gt#novel biomarkers#_lt#/span#_gt##_lt#/a#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt##_lt#span style="font-size#_sc# small;"#_gt# #_lt#/span#_gt#being discovered on an ongoing basis in academic research centers such as #_lt#/span#_gt##_lt#span style="font-size#_sc# small;"#_gt##_lt#span style="font-family#_sc# Arial; font-size#_sc# 10pt;"#_gt##_lt#a target="_blank" href="http#_sc#//www.ab.biomarcare.com/BRPortal/br/P102.jsp?arc=67057" target="_blank"#_gt##_lt#span style="font-size#_sc# small;"#_gt#Hadassah Medical Center#_lt#/span#_gt##_lt#/a#_gt##_lt#/span#_gt##_lt#/span#_gt# #_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt#, the company's "home base". The company intends to leverage its access to Hadassah's vast clinical research resources in order to conduct rigorous validation studies, and to utilize its executive team members' expertise in assay development to generate high performance diagnostic assays with proven clinical efficacy.#_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/div#_gt# #_lt#div style="text-align#_sc# justify; direction#_sc# ltr; color#_sc# #000000; font-size#_sc# 14px;"#_gt# #_lt#/div#_gt# #_lt#/span#_gt##_lt#/td#_gt# #_lt#td style="width#_sc# 50px;" align="right" valign="top"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#br#_gt##_lt#/span#_gt##_lt#/td#_gt# #_lt#/tr#_gt# #_lt#/tbody#_gt# #_lt#/table#_gt# #_lt#/div#_gt# #_lt#p#_gt##_lt#span style="font-family#_sc# verdana, geneva;"#_gt##_lt#span style="font-size#_sc# medium;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span style="color#_sc# #595454; font-weight#_sc# normal;"#_gt# #_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/p#_gt# #_lt#div style="text-align#_sc# left; font-weight#_sc# bold;"#_gt# #_lt#div style="text-align#_sc# left; direction#_sc# ltr; color#_sc# #000000; font-size#_sc# 14px;"#_gt##_lt#span style="font-family#_sc# arial, helvetica, sans-serif;"#_gt# #_lt#p#_gt# #_lt#/p#_gt# #_lt#/span#_gt##_lt#/div#_gt# #_lt#/div#_gt# #_lt#p#_gt##_lt#span style="color#_sc# #595454;"#_gt# #_lt#/span#_gt##_lt#/p#_gt# #_lt#p#_gt# #_lt#/p#_gt# #_lt#div style="text-align#_sc# left; font-weight#_sc# bold;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt#     #_lt#/span#_gt##_lt#a style="color#_sc# #000099; font-weight#_sc# bold; text-decoration#_sc# underline;" dir="ltr" href="http#_sc#//www.investors.biomarcare.com/BRPortalStorage/a/17/30/12-ZGySnMtLnz.pdf" target="_blank"#_gt##_lt#/a#_gt##_lt#span style="color#_sc# #595454;"#_gt#   #_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/div#_gt# #_lt#div style="text-align#_sc# left; font-weight#_sc# bold;"#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span#_gt##_lt#span style="color#_sc# #595454;"#_gt#  #_lt#/span#_gt##_lt#/span#_gt##_lt#br#_gt# #_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#/span#_gt##_lt#span#_gt##_lt#br#_gt##_lt#/span#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#/div#_gt# #_lt#p#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#br#_gt##_lt#/p#_gt#